News - Page 92 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Psychedelic Research Bulletin: July and August 2022

Psychedelic Research Bulletin: July and August 2022

Post published:September 5, 2022
Post category:Psychedelics Research Review

Read more about the article Wesana Announces Sale of Clinic Management Services Organization

Wesana Announces Sale of Clinic Management Services Organization

Post published:September 3, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

Post published:September 2, 2022
Post category:Press Release

Read more about the article COMPASS Pathways to participate in three upcoming investor events

COMPASS Pathways to participate in three upcoming investor events

Post published:September 1, 2022
Post category:Press Release

Read more about the article Optimi Health Provides Progress Report On Year Of Commercialization

Optimi Health Provides Progress Report On Year Of Commercialization

Post published:September 1, 2022
Post category:Press Release

Read more about the article FILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN HEALTH CANADA-APPROVED PSILOCYBIN CLINICAL TRIAL

FILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN HEALTH CANADA-APPROVED PSILOCYBIN CLINICAL TRIAL

Post published:September 1, 2022
Post category:Press Release

Read more about the article Reunion Neuroscience Inc. Announces 2022 Annual General Meeting of Shareholders

Reunion Neuroscience Inc. Announces 2022 Annual General Meeting of Shareholders

Post published:September 1, 2022
Post category:Press Release

Read more about the article Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Post published:August 31, 2022
Post category:Press Release

Read more about the article Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds

Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds

Post published:August 31, 2022
Post category:Press Release

Read more about the article Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

Post published:August 31, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.